Combining a gilteritinib analogue PROTAC targeting FLT3 ITD with venetoclax demonstrates increased synergistic anti-AML effects in vivo, with lower normal tissue toxicity compared to gilteritinib and venetoclax together. Here, FLT3 is linked to acute myeloid leukemia.